(Q40329901)

19 September 2017

title

Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia (English)

1 reference

19 September 2017

main subject

piperacillin/tazobactam

1 reference

Mizuho Ichikawa

1

1 reference

19 September 2017

Daisuke Suzuki

2

1 reference

19 September 2017

Junjiro Ohshima

3

1 reference

19 September 2017

Yuko Cho

4

1 reference

19 September 2017

Makoto Kaneda

5

1 reference

19 September 2017

Akihiro Iguchi

6

1 reference

19 September 2017

Tadashi Ariga

7

1 reference

19 September 2017

publication date

24 March 2011

1 reference

19 September 2017

published in

Pediatric Blood Cancer

1 reference

19 September 2017

volume

57

1 reference

19 September 2017

issue

7

1 reference

19 September 2017

page(s)

1159-1162

1 reference

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

19 September 2017

cites work

1 reference

Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group

21 January 2018

1 reference

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

21 January 2018

1 reference

Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis

21 January 2018

1 reference

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

21 January 2018

1 reference

Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey

21 January 2018

1 reference

Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison

21 January 2018

1 reference

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

21 January 2018

1 reference

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients

21 January 2018

1 reference

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

21 January 2018

1 reference

A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies

21 January 2018

1 reference

Cefepime versus ceftazidime: considerations for empirical use in critically ill patients

21 January 2018

1 reference

Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors

21 January 2018

1 reference

A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders

21 January 2018

1 reference

Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients

21 January 2018

1 reference

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study

21 January 2018

1 reference

Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children

21 January 2018

1 reference

Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children

21 January 2018

1 reference

Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.

21 January 2018

1 reference

Resistance to imipenem in Pseudomonas aeruginosa.

21 January 2018

1 reference

Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections

21 January 2018

1 reference

Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients

21 January 2018

1 reference

The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.23106

1 reference

release_clkg45o7uvhntlyyibdar43wxa

19 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/clkg45o7uvhntlyyibdar43wxa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference